This review offers a perspective on the future of paediatric sedation. This future will require continued evaluation of adverse events, their risk factors, and predictors. As the introduction of new sedatives with paediatric applications will remain limited, the potential role of mainstay sedatives administered by new routes, for new indications, and with new delivery techniques, should be considered. The role of non-pharmacological strategies for anxiolysis, along with the application of non-mainstay physiologic monitoring, may aid in the improvement of targeted sedation delivery. Understanding the mechanism and location of action of the different sedatives will remain an important focus. Important developments in paediatric sedation will require that large scale studies with global data contribution be conducted in order to support changes in sedation practice, improve the patient experience, and make sedation safer.
Necessary steps to decrease sedation-related adverse events include a global unified approach to data collection and reaching consensus on guidelines. Anxiolysis, using pharmacological and nonpharmacological techniques, is an important adjunct to sedation. ADV6209, recently approved as a paediatric anxiolytic in Europe, may be an alternative to midazolam. Considerations of new delivery techniques and implementation of non 'Standard of Care' physiological monitors may advance the ability to target sedation goals.
Significant advances and changes have occurred over the past few years in paediatric sedation, as the array of procedures, patients, proceduralists, locations, sedation techniques, approaches, guidelines, and agents expand quickly. There have recently been important changes in specialty guidelines and statements apropos to sedation both in the USA and abroad. From the use of chloral hydrate to the recent introduction of ADV6209, and those drugs still in development, the quest for an ideal sedative with rapid onset, predictable efficacy, and a low adverse event profile, continues.
The field of paediatric sedation within and outside the hospital setting continues to expand. It includes painful and non-painful procedures. This review will present an overview of recent initiatives and changes in the area of paediatric sedation and will support the need for a unified global approach to practice.
Importance of appropriate pre-sedation evaluation and assessment to triage those at high risk of adverse outcomes Improving safety requires an up-to-date evaluation of those factors which may be contributing to adverse outcomes. There continues to be a low, but consistent incidence of adverse events associated with sedation. Airway-and respiratoryrelated events comprise the majority of sedation and anaesthesia-related cases of morbidity and mortality. 1 A retrospective review of airway events from 83 491 paediatric procedural sedations suggests that the presence of an upper respiratory tract infection within the past 2 weeks increases the risk of airway events from 6.3% to 9.1%. The risk increases with the presence of clear (14.6%) and thick (22.2%) secretions. 2 The risks of sedation are not the same between sedatives. A retrospective review of more than 16 000 sedations, predominantly with pentobarbital and chloral hydrate, revealed that 30% of those with adverse events had a past history of significant respiratory illness. 3 A review of 16 467 paediatric sedations (mostly pentobarbital and chloral hydrate) reported an overall rate of 0.4% adverse events, with 58 oxygen desaturations and 10 cases of needing brief positive pressure ventilation. 4 A meta-analysis of 8282 children who received ketamine reported that predictors for adverse airway and respiratory events included high i.v. doses, administration to children <2 or >13 yr, and the co-administration of anticholinergics or benzodiazepines. 5 Combining propofol with ketamine resulted in a 3.5% incidence of adverse events in 7313 children (mean age 7 yr). 6 A careful pre-sedation evaluation which specifically focuses on the presence of upper respiratory infections and the nature of existing secretions should remain the predominant mainstay of ensuring safety, even before the administration of a sedative. A single drug should be used when possible.
Sedation and anxiolysis: a holistic approach with non-pharmacologic and pharmacologic options Anxiolysis, using pharmacologic and non-pharmacologic approaches together, has an important role in procedural sedation. Anxiety can have a detrimental effect on sedation and on anaesthesia. In the anaesthesia literature, anxiety increases the likelihood of emergence delirium and agitation immediately after anaesthesia, and of maladaptive behaviours for up to 2 weeks. 7 Diminishing anxiety may also have an important role not only for the procedure at hand, but also for future procedures and sedation encounters. Recently, alternative non-pharmacologic and pharmacologic strategies have been proposed. A Cochrane review of 39 randomised controlled trials with 3394 participants (2e19 yr) reported that the most commonly studied psychological interventions for needle procedures were distraction, hypnosis, and cognitive behavioural therapy. 8 Music therapy, video games, iPads, pre-sedation information provided in entertaining, child-friendly format, acupuncture, hypnosis, clowns, magic, and child life specialists on site are all techniques that have reported success.
8e10 Video distraction has even been shown, in a prospective randomised trial of 2e12-yr-olds, to be as effective as oral midazolam for anxiolysis. 11 There is some indication that active engagement of the child, using an iPad for example, may be superior to passive engagement (e.g. video goggles) in reducing anxiety and acceptance of procedural stimulation. 12 Diminishing sensory stimulus by dimming lights and introducing music during the procedure can decrease anxiety, increase compliance, and even decrease propofol requirements. 13 14 Child life specialists, in prospective trials of children between the age of 1 and 12 yr, can play an important role in relieving anxiety, distress, perception of pain, and in improving parental and patient experience. 15 Non-pharmacologic approaches may not be successful for all children, and there will always remain the occasions that necessitate pharmacologic interventions before the administration of sedation. The future of sedation requires that alternatives to the traditional midazolam approach be considered. Although historically benzodiazepines have been the mainstay, ketamine has most recently been reconsidered and evaluated for anxiolysis. A prospective randomised double-blind study of 2e8-yr-olds suggests that within approximately 20 min of administration, oral ketamine (5 mg kg
À1
) produces better anxiolysis than oral midazolam (0.5 mg kg
). Ketamine should be considered as an important alternative to midazolam, with an added benefit of analgesia. 16 Dexmedetomidine (DEX) also offers an alternative to midazolam. Via the intranasal route (atomiser preferable), DEX has been described as being at least as effective as midazolam as an anxiolytic. A dose of intranasal DEX 1 mg kg À1 has been shown to achieve adequate sedation in 25 min, lasting for up to 100 min (median duration 85 min) in 62% of children for i.v. cannulation with topical local anaesthetic already applied. 17 for anxiolysis. 21 Recently there has been a promising option to midazolam, approved uniquely in Europe, for paediatric anxiolysis. ADV6209 (Ozalin, Primex Pharmaceuticals, Zug, Switzerland), with clinical studies limited to date only in Europe, was approved in September 2018 for children more than 6 months of age. ADV6209 offers an alternative to the parenteral and enteral form of midazolam hydrochloride, which has been the mainstay since approved for paediatric administration in the USA in 1995 (parenteral) and 1998 (enteral). Labelled for paediatric use, oral midazolam hydrochloride in its unaltered form is not palatable. ADV6209 offers the advantage that it is a 0.2% aqueous midazolam formulation which is formulated with a gamma-cyclodextrin complex to mask the bitterness and is combined with sucralose and orange aroma. The recommended dose is 0.25 mg kg À1 (maximum 20 mg). The oral bioavailability of ADV6209 is 39.6% in healthy adults, with a half-life of 2.66 h, onset in 27.5 min, and duration of 48.5 min. 22 Pharmacokinetic single dose studies in adults and children report that 77% of the oral dose is absorbed within 30 min, with the cyclodextrin having no significant effect on the pharmacokinetics. 23 ADV6209 represents the first sedative with paediatric labelling approved for more than a decade and could offer promise for paediatric procedural sedation.
Sedatives in development
There are some sedatives in development which may offer promise for paediatric sedation. Remimazolam, identified as CNS 7056, is an ultra-short-acting benzodiazepine that is metabolised by tissue esterases into inactive metabolites.
In vitro studies document binding to gamma-aminobutyric acid A sites in the brain. Its effects may be reversed by flumazenil. The first human study was published in 2012, the phase-1 trial, which was a single centre, double blinded trial on healthy adults. Compared with midazolam, remimazolam exhibited faster recovery (10 vs 40 min), faster clearance and dose-dependent sedation with haemodynamic and respiratory sparing. 24 Phase-2 trials to assess safety and efficacy in adults included double blind studies comparing outcomes with midazolam for upper and lower gastrointestinal endoscopies. Remimazolam exhibited faster onset, faster recovery, and greater success (64% vs 44%). No significant adverse events were reported. 25 Etomidate derivatives are in design and study now, with goals of altering the parent structure in order to eliminate or mitigate known side-effects of adrenocortical suppression, myoclonus, and nausea/vomiting. Cyclopropyl-methoxycarbonyl metomidate (ABP-700), an etomidate analogue, has been shown in a phase-1 study of adult volunteers to demonstrate a dose- ) reported mild dose-dependent tachycardia, dosedependent sedation, slightly elevated BP, and no centrallymediated apnoea or adrenocortical depression. IMM were dose-dependent. Future studies in paediatrics need to determine whether there is similar dose-dependent, respiratory sparing, success in achieving moderate sedation with ABP-700, and whether IMM would limit the ability to achieve optimal procedural conditions. 27 Both remimazolam and the etomidate derivatives, albeit in the development phase and still being tested in the adult population, offer the hope of providing sedation with minimal effect of respiration. Respiratory depression remains a significant contributor to sedation-related adverse events, and the continued quest for respiratory sparing sedatives will remain important.
New applications for ketamine
The future of sedation will not only introduce new sedatives, but will also consider the application of sedatives (both old and new) for 'applications', not all of which may be for procedures. One example is the recent growing interest in the potential role of ketamine in the treatment of major depression, particularly those cases which have been resistant to treatment. With the majority of studies currently limited to the adult population, a randomised controlled trial has demonstrated that in adults with major depressive disorder (MDD), i.v. ketamine (0.5 mg kg À1 ) is superior to i.v. midazolam (0.02 mg kg À1 ) in decreasing suicidal ideation and improving mood state within 24 h, with lasting effects up to 6 weeks. 28 A meta-analysis of the effect of single dose i.v. ketamine on suicidal ideation reported that ketamine had a moderate to large effect on decreasing suicidal ideation as soon as 24 h and up to 1 week. 29 Recently, the application of ketamine for adolescents has become of interest. An open label study administered six doses i.v. ketamine of 0.5 mg kg À1 to a small (n¼13) group of adolescents (12e18 yr) with treatment-resistant depression. Some 38% responded with improvement in their depressive symptoms for 2e6 weeks. 30 A recent randomised, double blind, placebo controlled trial showed that adults with suicidal ideation and treatmentresistant MDD do not respond to six treatments of i.v. ketamine (0.5 mg kg À1 ). 31 Further studies are needed to determine whether higher doses of ketamine are required for severe, treatment-resistant MDD.
Understanding how and where sedatives work at the level of the CNS has become an important area. With the development of new neuroimaging techniques, we have expanded our ability to examine the different sedatives. One example is the examination of ketamine with respect to depression; a review of 47 publications, all of which used neuroimaging, revealed that there is more than one area of the brain attributed to ketamine's antidepressant effects. Patients with MDD responded to ketamine by increasing connectivity in the lateral prefrontal cortex, caudate, and insula. There is speculation that these findings indicate ketamine's ability to alter input from the frontal cortex to the limbic areas in order to affect the relationship between cognition, emotion, and symptoms of MDD. 32 Ketamine wellness centres that offer i.v. ketamine for treatment for depression are currently being offered in freestanding offices and major academic institutions in the USA. The future will determine whether there is a role for ketamine and a sedation provider in using ketamine for MDD of the paediatric population.
Recent update in nil-by-mouth guidelines
A re-evaluation of guidelines is another important initiative. Improving the patient experience, by decreasing the nil-bymouth (NBM) guidelines, has become an area of increased interest (and controversy). Traditionally, NBM status for sedation follows the same guidelines as for anaesthesia, with the exception of children who receive sedation in the emergency departments. The most recent guidelines for emergency medicine NBM are founded on patient risk factors, urgency of procedure, and depth of sedation anticipated in order to complete the procedure. 33 Despite guidelines, most patients for procedural sedation present with longer fasting times than recommended. A UK study of 1350 children (<16 yr) reported fasting times of 12 and 8 h for solids and liquids, respectively.
34
In infants (<36 months), prolonged fasting can result in ketoacidosis. 35 Adopting anaesthesia NBM guidelines and applying them for procedural sedation may not be necessary to decrease the aspiration risk. In a large, multicentre, prospective, cohort study of more than 6000 children (<18 yr) who received sedation in the emergency department, there was no aspiration, although 48% and 5% did not meet ASA NBM guidelines for solids and liquids, respectively. 36 In a large, retrospective, multicentre review of just under 140 000 paediatric sedations, 0.97 aspiration events per 10 000 procedures were reported, of which 23.5% of the children were not NBM. The NBM status was not a predictor of aspiration or major adverse events. 37 A review of the literature supports that gastric emptying in children can occur in less than 2 h for clear fluids. 38 Three European societies of paediatric anaesthesia recently issued a joint consensus statement, reducing the NBM for clear fluids to 1 h for elective general anaesthetics in healthy children without aspiration risk factors. 39 To date, the ASA has not modified their fasting guidelines. The updated Practice Guidelines for Moderate Procedural Sedation and Analgesia of 2018 supports 2-h clear, 4-h breast milk, 6-h infant formula, and 6-h 'light foods.' 40 Using large, data-driven studies to support a change in sedation-related guidelines, NBM included, and achieving a consensus between specialties and continents, should remain a goal of sedation providers.
Radiologic imaging to determine mechanisms of sedatives
The application of neuroimaging to elucidate not only the mechanisms and targets of action, but also their effects on hypnosis and memory, has become of growing interest. The effect and mechanism of sedatives on the CNS may continue to be better understood using functional MRI and future expansions of radiologic imaging. Functional MRI (fMRI) studies in adults have supported that the connections between the locus coeruleus and posterior cingulate cortex, thalamus, and basal ganglia modulate arousal and sedation. 41 The mechanism of DEX, and its ability to simulate non-rapid eye movement sleep, for example, has been shown to differ from the effect of propofol sedation. Using fMRI, the thalamic functional connectivity with the medial prefrontal/anterior cingulate cortex and with the mesopontine area was reduced the least with DEX sedation and the most during propofol. Subsequently, the effect of DEX on the thalamic pathways during sedation have begun to be mapped. 42 43 Another recent prospective fMRI study examined functional connectivity during escalating doses of propofol sedation. Interestingly, propofol suppressed activity in areas of the brain that were sparsely connected. 44 
New techniques for sedation delivery
Target-controlled infusions (TCI) may represent the future of paediatric sedation. In paediatrics, a significant challenge to TCI has been to identify models that best fit children over a variety of ages. Recently, a model was developed with propofol that reviewed 30 studies and included 199 children. It was successful at predicting propofol concentrations over a variety of ages and may open paths for administering TCI propofol from infancy through adolescence, and potentially could even facilitate its use for short procedures in the emergency department. 45 46 Closed-loop delivery systems offer the advantage of providing a feedback to the delivery system which may then adjust the delivery. A multicentre, randomised trial with propofol administered via closed-loop or manual administration, using targeted BIS demonstrated more consistent performance and a longer period of achieving target BIS with the closed-loop groups. Closed-loop administration of propofol may assume some importance in sedation in the future. 47 48 Integrating TCI and closed-loop delivery to improved patient safety Different procedures will have different requirements for depths of sedation. Furthermore, each procedure will have varying needs for depth of sedation over its duration. With precise pharmacokinetic and pharmacodynamic studies, tailored to the different procedures, it may be possible to more effectively target TCI and closed-loop delivery to the procedure. This precision has been attempted with paediatric MRI; the effect-site concentration (Ce) of propofol was simulated during the preparation, scanning, recovery, and occurrence of adverse events. Higher Ce were needed during the preparation phase with the application of physiological monitors than during the scanning phase. Ce 95 , 1.43 mg ml À1 was determined to be an adequate concentration for MRI sedation. Oxygen desaturation, hypotension, and bradycardia were associated with propofol Ce of 3.01 (0.04), 2.05 (0.63), and 2.41 (0.89) mg ml
À1
, respectively. 49 For upper endoscopies, TCI models have also been used to determine that the median effective dose of propofol needed is 3.55 mg ml À1 in a cohort of children 3e10 yr of age. 50 
Application of new monitors and clinical signs in order to improve sedation
In addition to the standard of care monitors applied for sedation, there is a growing interest in the role of other noninvasive physiologic monitors as a means to titrate and monitor sedation and follow clinical responses. Each of the potential monitors will be explored below, presenting the most relevant data in support of their application and future in paediatric sedation.
Using EEG to guide sedation
Neurological monitoring has been used for adult sedation as a means to titrate sedation and for research purposes, to evaluate efficacy, and to compare pharmacokinetics and pharmacodynamics; BIS monitoring has been used to determine that there is a dose-dependent decrease in BIS levels with ABP-700 in a phase 1 trial, to evaluate the performance of propofol sedation with closed-loop systems, and to evaluate relationships between Ce of propofol and fluctuations in hemodynamics. 26.51e53 Most recently, BIS has been used to develop a pharmacokinetic-pharmacodynamic model for propofol which is applicable to all age groups, children included. 45 In light of the established utility of BIS for adult sedation, and most recently for following paediatric sedation depths, consideration should be given to following BIS, particularly with propofol administration. BIS scores with propofol sedation in children have been shown to correlate well with the depth of sedation and with the modelled Ce in children >1 yr of age (Fig 1) . 54 Neurological monitoring may not be limited only to BIS monitoring. Children (12e17 yr) receiving TCI with propofol for gastrointestinal endoscopy had shorter recovery, less over-sedation, and less propofol usage when EEG has been followed with the Narcotrend®; Monitor Technik, Bad Bramstedt, Germany. 55 Continued studies are necessary to determine the extent of clinical and research applicability of neurological monitoring with paediatric sedation.
Pupillary reactivity
Pupillometry is a non-invasive means of assessing pupillary reflex dilatation induced by nociceptive stimulations. Pupillometry utilises an infrared camera to follow dynamic pupillary diameter. In general, pupillary diameter increases in response to nociceptive stimuli. 56 The pupil reactivity (diameter) in response to a standardised stimulus (tetanus) has been shown to have a good correlation with BIS levels in patients receiving TCI propofol-remifentanil. 57 Even with i.v. ketamine (1 mg kg
À1
) in combination with oral morphine (0.3 mg kg À1 ), pupillary reflex dilation persisted in response to nociceptive (and increasing) stimuli. 58 
Non-invasive respiratory monitors
Non-invasive respiratory monitors using impedance technology also show promise in identifying changes in minute ventilation that are not captured by capnography. Decreases in minute ventilation of up to 47.8%, which can be identified with impedance technology, would not have been captured with the corresponding decrease in end tidal CO 2 of only 5.2%. 59 
Pre-tracheal (cordial) stethoscope
The use of capnography has been recommended as part of monitoring with moderate sedation and its use has become more widespread. Together with capnography, the use of the pre-tracheal stethoscope as a simple, non-invasive and inexpensive monitor of each breath can be very sensitive to detecting subtle changes in respiration or airway compromise during sedation. In 2013, a review of trends in death associated with paediatric dental anaesthesia and sedation searched media reports from 1980 to 2011. A total of 44 deaths were reported in patients younger than 21 yr, with half of the deaths being in children aged 2e5 yr who were undergoing relatively simple procedures of fillings, crowns, and extractions. Forty-five percent of the deaths were reported while under moderate sedation. A higher percentage of deaths occurred in the officebased setting. 60 In paediatric dentistry, a prospective study in healthy children demonstrated that in conjunction with capnography, the pre-tracheal stethoscope doubled the ability to identify respiratory adverse events and decreased the false positive rate. 61 When logistically feasible, pre-tracheal stethoscopes offer an inexpensive, simple, non-invasive monitor of the patient's every breath, and a sensitive indicator of changes in respiratory effort, pulmonary status, or airway patency.
Sedation quality assurance outcomes as a global initiative
The collection of outcomes is an important initiative that is supported in all sedation guidelines across specialties. 62 63 In 2012, an International Sedation Task Force (ISTF) was formed with the intention of creating a standardised definition of adverse events which could be applied across all specialties and patient age groups and countries, in an effort to construct a 'common language' to identify adverse events. 64 The
Adverse Event (AE) Reporting Tool was born out of the ISTF consensus, providing sedation providers worldwide with a means of reporting and tracking their sedation outcomes using standardised definitions. The ISTF has since evolved into the International Committee for the Advancement of Procedural Sedation (ICAPS), keeping the chairs of the original committee and expanding the membership and expertise of the ICAPS (www.proceduralsedation.org). The AE Sedation Reporting Tool evolved into the Tracking and Reporting Outcomes of Procedural Sedation (TROOPS) Tool (www.TROOPSsedation.com) which is compliant with international standards (www.MedDRA.org) and has increased applicability for quality improvement and clinical research 64 65 (see Fig 2) .
The Food and Drug Administration (FDA), in an important initiative, recently formed a sedation consortium of national and international sedation experts from different specialties and representing both adult and paediatric populations. This consortium met several times in Washington DC with the intention of constructing endpoints to evaluate patientcentred sedation outcomes of efficacy and safety which could be used for treatment, education, and research purposes (clinical trials included). After consensus of the consortium It is possible that the Continuum of Depth of Sedation of 1999, amended in 2014, should be reformulated. 70 Originally constructed to evaluate responsiveness to auditory and tactile stimulation as a surrogate marker of risk of respiratory depression, the sedation continuum may be ready for a complete reformulation. With quality improvement data and data from applied physiological monitoring, the manner in which sedation is defined and characterised could better reflect the concurrent risk of airway and cardiovascular compromise. 71 
Discussion
The area of paediatric sedation continues to evolve, still holding onto some of the 'old' sedatives such as chloral hydrate (which continues to play an important role, particularly in sedation for cardiac echocardiograms and EEGs). 72 The evolution of radiologic imaging holds promise at uncovering the areas of the brain and mechanisms of action of the different sedatives.
41e44 This will also be important as we try to discern the mechanisms and locations of action of different sedatives. Establishing standards of care for the physiological monitoring of the sedated child, across specialties, has now been achieved, especially notable with the recent adoption of capnography for moderate sedation. 40 There still remains work to be done on establishing guidelines and criteria for sedation training. There are currently no universally-accepted competency-based formal training recommendations. Future work needs to focus on determining the training and education that is needed to optimally deliver sedation at different targeted depths for different procedures, venues, and patient populations. The future of paediatric sedation relies on the collecting and sharing of quality assurance data on a large scale between specialties and countries in order to evaluate and improve sedation practice and outcome. This mission has been emphasised in all updated sedation guidelines across specialties and continents. As sedation becomes safer, determining with accuracy the incidence and aetiology of adverse events will require large cohorts of patients. Currently, sedation-related guidelines are not consistent between specialties, societies, and countries. Understanding the risks of sedation-related adverse events will lead us closer to reaching a consensus towards specialty-appropriate universal sedation guidelines. Patient and parent experience, and level of satisfaction are equally important considerations for future sedation practice. One example of this is the recently updated European NBM guidelines. 7 By decreasing the NBM guidelines for clear liquids, a shorter fasting time will improve the patient experience. With careful consideration of outcome data, important and significant changes in what has historically been dogma may be changed, and perhaps, someday, universally adopted. The formation of first the ISTF and then its evolution and expansion to the ICAPS, reflect important initiatives in assembling multi-specialists for both adults and children, across the continents. The subsequent adaption of TROOPS as a means to track sedation outcomes will advance the quality improvement initiative in conjunction with the Sedation Consortium on Endpoints and Procedures for Treatment, Education and Research (SCEPTER) of the US FDA.
Conclusions
Paediatric sedation should focus on collaborative strategies that improve patient (and parent/caregiver) experience, and on improving patient safety and outcomes. The fundamentals of safe sedation lie in the early detection and management of impending adverse events. Exploring adjunctive means to monitor depth of sedation, and to apply alternative means of sedation delivery with TCI and closed-loop delivery systems, are key to shaping the future of paediatric sedation.
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